CIAM
LAB icon

Caitong International Asset Management’s Standard BioTools LAB Stock Holding History

Caitong International Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-164
-99% -$199 ﹤0.01% 2488
2025
Q4 		$211 Buy
+165
New +$222 ﹤0.01% 1611
2025
Q3 		– Sell
-1,932
Closed -$2.32K – 2248
2025
Q2 		$2.32K Buy
+1,932
New +$2.14K ﹤0.01% 1332

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Caitong International Asset Management's LAB Position: Q1 2026 in Review

Caitong International Asset Management reduced its Standard BioTools (LAB) stake by 99% in Q1 2026, selling an estimated $199 and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Caitong International Asset Management first reported a position in LAB in Q2 2025 and has held it in 3 quarters since. The position peaked at $2.32K in Q2 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Caitong International Asset Management held 1 share of Standard BioTools worth $1 as of Q1 2026.
  • Caitong International Asset Management sold 164 Standard BioTools shares in Q1 2026, an estimated $199.
  • Standard BioTools made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2488 holding.
  • Caitong International Asset Management first reported a position in Standard BioTools in Q2 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's Standard BioTools position peaked at $2.32K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.